Results 211 to 220 of about 44,965 (296)

Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction. [PDF]

open access: yesNeuropharmacology, 2020
Wittenberg RE   +3 more
europepmc   +1 more source

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

open access: yesAddiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor   +7 more
wiley   +1 more source

How the sales of oral nicotine pouches correlate with prices and respond to taxes on cigarettes and e‐cigarettes

open access: yesAddiction, EarlyView.
Abstract Background and aims Oral nicotine pouches (ONPs) have seen a dramatic rise in sales since their introduction to the US market in 2016. We aimed to define the relationship between ONP prices and sales (e.g. price elasticity of demand) and determine how taxes on cigarettes and e‐cigarettes (ECs) impact ONP sales.
Yanyun He   +7 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden   +10 more
wiley   +1 more source

Role of corticotropin-releasing factor in alcohol and nicotine addiction. [PDF]

open access: yesBrain Res, 2020
Simpson S   +3 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

open access: yesAddiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

open access: yesAddiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy